Alan Fuhrman Purchases 9,500 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Alan Fuhrman bought 9,500 shares of the stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at approximately $205,584. The trade was a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $16.39 on Friday. The company has a market cap of $865.56 million, a PE ratio of -9.70 and a beta of 1.08. The firm has a fifty day moving average price of $22.39 and a two-hundred day moving average price of $19.88. Tyra Biosciences, Inc. has a fifty-two week low of $10.60 and a fifty-two week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.09. Analysts expect that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on TYRA shares. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. HC Wainwright raised their target price on shares of Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Piper Sandler began coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price for the company. Finally, Oppenheimer raised their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.40.

Institutional Trading of Tyra Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of TYRA. HighVista Strategies LLC bought a new position in Tyra Biosciences in the second quarter worth $257,000. SG Americas Securities LLC acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at $311,000. Rhumbline Advisers lifted its holdings in shares of Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after acquiring an additional 2,574 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Tyra Biosciences by 32.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Tyra Biosciences during the 1st quarter valued at about $977,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.